Nabriva Therapeutics Plc Long Term Debt

Nabriva Therapeutics Plc (NBRV) currently reports a long-term debt of $350K as of March 2023. That compares with $3.9M in the prior-year period — down 91.2% year over year. Use the charts on this page to explore Nabriva Therapeutics Plc's long-term debt history and peer comparisons.

Nabriva Therapeutics Plc's long-term debt decreased from $3.9M to $350K — a 91.2% year-over-year decrease (period ending March 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Nabriva Therapeutics Plc reported $350K in long-term debt as of March 2023. That compares with $3.9M in the prior-year period — down 91.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $350K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Nabriva Therapeutics Plc, and consider following NBRV for alerts when major investors trade the stock.

Nabriva Therapeutics Plc is classified in the Healthcare sector. On long-term debt, it currently shows $350K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing NBRV with unrelated industries.